We report an in vivo study of the effects of Oxy210, an oxysterol inhibitor of Hh and TGF‐β signalling, on hepatic fibrosis using a mouse model that displays many of the features and molecular signatures characteristic of human NASH pathophysiology.14 Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.